NANOFOL
Folate-based nanobiodevices for integrated diagnosis/therapy targeting chronic inflammatory diseases
| Coordinatore | UNIVERSIDADE DO MINHO
Organization address
address: Largo do Paco contact info |
| Nazionalità Coordinatore | Portugal [PT] |
| Sito del progetto | http://www.nanofol.eu/ |
| Totale costo | 6˙635˙409 € |
| EC contributo | 5˙149˙874 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2008-LARGE-2 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-12-01 - 2013-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSIDADE DO MINHO
Organization address
address: Largo do Paco contact info |
PT (BRAGA) | coordinator | 1˙054˙530.00 |
| 2 |
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
Organization address
address: 101 Rue de Tolbiac contact info |
FR (PARIS) | participant | 522˙780.00 |
| 3 |
INSTITUT NATIONAL DE L ENVIRONNEMENT ET DES RISQUES INERIS
Organization address
address: Parc Technologique Alata contact info |
FR (VERNEUIL EN HALATTE) | participant | 468˙319.00 |
| 4 |
NEDERLANDSE ORGANISATIE VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Organization address
address: Schoemakerstraat 97 contact info |
NL (DEN HAAG) | participant | 453˙858.53 |
| 5 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 452˙432.56 |
| 6 |
EXBIO PRAHA AS
Organization address
address: Nad Safinou II 341 contact info |
CZ (VESTEC) | participant | 418˙175.60 |
| 7 |
SYNOVO GMBH
Organization address
address: Paul Ehrlich Str 15 contact info |
DE (TUEBINGEN) | participant | 368˙373.90 |
| 8 |
INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR - IBMC
Organization address
address: RUA DO CAMPO ALEGRE 823 contact info |
PT (PORTO) | participant | 314˙437.56 |
| 9 |
TECHNISCHE UNIVERSITAET GRAZ
Organization address
address: Rechbauerstrasse 12 contact info |
AT (GRAZ) | participant | 304˙036.84 |
| 10 |
UNIVERSITATEA AUREL VLAICU DIN ARAD
Organization address
address: BULEVARD REVOLUTIEI 77 contact info |
RO (Arad) | participant | 285˙175.25 |
| 11 |
ALMA CONSULTING GROUP SAS
Organization address
address: Domaine des Bois d'Houlbec contact info |
FR (HOULBEC COCHEREL) | participant | 213˙007.00 |
| 12 |
UNIVERSITAET FUER BODENKULTUR WIEN
Organization address
address: Gregor Mendel Strasse 33 contact info |
AT (WIEN) | participant | 147˙407.69 |
| 13 |
SUAN FARMA S.A.
Organization address
address: Einstein 8 contact info |
ES (Alcobendas) | participant | 125˙572.55 |
| 14 |
"Alfama - Investigacao e Desenvolvimento de Produtos Farmaceuticos, Lda."
Organization address
address: "Av. da Republica, Quinta do Marques, Estacao Agronomica Nacional IBET/ITQB, Lab.7.14" contact info |
PT (Oeiras) | participant | 21˙767.53 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'NANOFOL proposes to develop a new diagnostic/therapy approach using folate based nanobiodevices (FBN) able to provide a new type of cost efficient treatment for chronic inflammatory diseases such as Atherosclerosis and Rheumatoid Arthritis with low side effects that will constitute a more advantageous solution than current therapies. NANOFOL will achieve all that by fulfilling the following objectives: •Design , development and production of nanobiodevices (FBN) targeting directly effector cells •Proof of concept in vitro and in vivo of a folate based nanodevice targeting activated macrophages in chronic inflammation not affecting bystander cells •Proof of concept in vitro and in vivo of a nanodevice containing a bispecific antibody (against folate receptor and another macrophage marker) targeting activated macrophages in chronic inflammation not affecting bystander cells •Proof of concept of FBN delivery therapeutic agents (by small interfering ribonucleic acid molecules (siRNA) or lipophylic molecules) targeting inflammatory signaling pathways •In vitro and in vivo testing of cellular toxicity caused by the novel nanobiodevices in cells other than activated macrophages •Design of models that will enable to minimize animal experimentation. •Development of a strategy to assess potential risks in order to ensure nanobiodevice safe delivery. NANOFOL has adopted a specific risk strategy to attain objectives in a step by step approach allowing improving gradually the concept (specificity, stability, side effects efficacy) from the lower to the higher risky solutions ensuring reduced experimental animal testing and high human safety. The NANOFOL project will combine expertise in nanotechnologies, biology, chemistry, materials science, biotechnology, engineering, risk analysis, medical and pharmaceutical sciences.'
Introduzione (Teaser)
Chronic inflammatory diseases like rheumatoid arthritis (RA) affect over 80 million people worldwide. Anti-arthritis drugs in current use have limited efficacy and are associated with high costs, allergic reactions and potentially lethal side-effects.